Molecular diagnostics company unlike others due to a secured suite of composition of matter IP. The technology is disease state agnostic, detects to single molecule level, scales easily to point of care, & provides favorable cost structure. First application-early detection of pancreatic cancer-is assay that will quickly prove the investment thesis due to large unmet medical need & favorable reimbursement. Stage: prototype/proof of concept data.